CD19 Research Products

CD19, a cell surface protein specific to B cells, has emerged as an effective immunotherapy target to treat B cell malignancies and autoimmune diseases.

By leveraging monoclonal antibodies, chimeric antigen receptor (CAR) T cells and NK cells, or bispecific T cell/NK cell engagers (BiTEs/BiKEs), CD19-directed immunotherapies aim to selectively eliminate CD19-expressing cells. In cancer, these therapies have shown remarkable efficacy in treating B cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), leading to durable remissions in many patients. Furthermore, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, targeting CD19 has demonstrated potential in rebalancing aberrant immune responses. This targeted approach offers a promising avenue for precision medicine, with ongoing research focused on refining therapeutic strategies and expanding the scope of CD19-directed immunotherapy.